Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice

Periodontitis Clinical Trial

— PAAS  

Official title:

Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice: A PBRN Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06131021
• Other study ID #: Pro2023001347
• Secondary ID: 4UH3DE031129-02
• Status: Recruiting
• Phase: Phase 3
• Start date: April 25, 2024
• Est. completion date: May 26, 2026

Study information

• Verified date: May 2024
• Source: Rutgers, The State University of New Jersey
• Contact: Varvara Chrepa, DDS, PhD
• Phone: 973-972-7331
• Email: vc551[@]sdm.rutgers.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Periodontitis is a bacterial inflammatory disease and antibiotic use is being empirically used as part of its treatment. However, a clinical practice guideline on periodontal treatment adjuncts published in 2015 identified weak evidence on the use of systemic antibiotics and large heterogeneity across small scale studies, suggesting that larger pragmatic clinical trials would benefit clinical decision making. This will be a prospective, randomized, placebo-controlled trial, stratified by practice and practitioner. The study will investigate the effectiveness of adjunctive antibiotics as adjunct to scaling and root planing (SRP) compared to SRP with placebo for the treatment of generalized stage II-III, grades A-C periodontitis in approximately 544 patient participants from about 34 National Dental PBRN practices. Periodontal data will be collected at baseline, re-evaluation (6 weeks), and final (12 months) study visits. Changes in periodontal clinical and patient-reported outcomes will be assessed to determine the effectiveness of SRP plus adjunctive systemic Amoxicillin / Metronidazole antibiotics (AMXM) versus SRP with Placebo.

Description:

Précis: Periodontitis is a bacterial inflammatory disease and antibiotic use is being empirically used as part of its treatment. However, a clinical practice guideline on periodontal treatment adjuncts published in 2015 identified weak evidence on the use of systemic antibiotics and large heterogeneity across small scale studies, suggesting that larger pragmatic clinical trials would benefit clinical decision making. This will be a prospective, randomized, placebo-controlled trial, stratified by practice and practitioner. The study will investigate the effectiveness of adjunctive antibiotics as adjunct to scaling and root planing (SRP) compared to SRP with placebo for the treatment of generalized stage II-III, grades A-C periodontitis in approximately 544 patient participants from about 34 National Dental PBRN practices. Periodontal data will be collected at baseline, re-evaluation (6 weeks), and final (12 months) study visits. Changes in periodontal clinical and patient-reported outcomes will be assessed to determine the effectiveness of SRP plus adjunctive systemic Amoxicillin / Metronidazole antibiotics (AMXM) versus SRP with Placebo.

Objectives and Outcomes: Primary: The primary objective will assess the effectiveness of SRP plus adjunctive antibiotics compared to SRP with placebo in periodontitis individuals from baseline to 6 weeks and 12 months following non-surgical periodontal therapy (NSPT) as determined by changes in site-level periodontal probing depth (PD).

Secondary: To assess changes in: i) gingival inflammation (measured by bleeding on probing (BoP)), ii) periodontal tissue attachment (measured by clinical attachment level (CAL)), iii) reduction in diseased sites (measured by remaining sites with maximum probing depth ≥5 mm), and iv) disease remission (measured by number of participants with ≤4 sites with PD≥ 5mm); comparing SRP plus AMXM to SRP with a placebo adjunctive in periodontitis individuals from baseline to re-evaluation (6 weeks) to final (12 month) study visit following intervention. The patient-reported impact of periodontal treatment (measured by the Oral Health Impact Profile-5 (OHIP-5)) and treatment-related adverse events between groups will also be assessed.

Population: The sample size will be a target of approximately 544 patient participants enrolled from approximately 34 National Dental PBRN practices. All patient participants are indicated to receive SRP and have been diagnosed with periodontitis stages II-III, grades A-C.

Description of Intervention: The intervention will involve either SRP, which is considered the standard of care treatment for debriding root surfaces, in conjunction with 500 mg Amoxicillin and 500mg Metronidazole orally every 8 hours (q8h) for ten days following SRP or SRP with placebo.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 544
• Est. completion date: May 26, 2026
• Est. primary completion date: January 1, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• The study will recruit a target of 544 patient participants presenting for periodontal treatment within the National Dental PBRN practices participating in this study.

To be eligible to participate in this study, a potential patient participant must meet all the following criteria:

• Adult who is at least 40 years old.

• Presence of = 20 permanent teeth excluding 3rd molars.

• In good general health as evidenced by medical history (ASA Class I or II) per the practitioner.

• Planned to receive periodontal care for Generalized Stage II-III, Grade A-C periodontitis (previously Generalized Moderate to Severe Periodontitis) and a minimum of two quadrants of SRP (CDT code 4341) in practices participating in the National Dental PBRN.

• Willing to comply with all study visits and be available for the duration of the study (12-15 months)

• Willing to provide contact information for self, including a cellular phone number for study text, and one to two emergency contacts to be reached for the follow-up visits and any other study-related matters for the duration of the study.

Exclusion Criteria:

• Known drug allergy to any antibiotics or anesthetics.

• Use of systemic antibiotics taken within the previous 3 months prior to enrollment.

• Medical condition which requires antibiotic prophylaxis prior to dental treatments/visits.

• Current use of medications that, in the opinion of the practitioner, may cause adverse effects with AMXM (such as disulfiram, warfarin, and oral contraceptives).

• History of any periodontal therapy (including SRP D4341, D4342) within the last 6 months prior to enrollment.

• Is currently pregnant or lactating per patient participant self-report.

• Is considered immunocompromised, in the opinion of the practitioner (including diseases and conditions such as HIV/AIDS, immunosuppressive drug therapy and/or radiation), or has chronic mucosal lesions (e.g. pemphigus vulgaris) affecting the gingiva.

• Has Diabetes mellitus with an HbA1c score of >/= 10% within the past 3 months as per patient participant self-report.

Related Conditions & MeSH terms

• Periodontal Diseases
• Periodontal Pocket
• Periodontitis

Intervention

Drug:
• Amoxicillin
Amoxicillin belongs to the penicillin category, and it is a commonly prescribed broad-spectrum antibiotic as a periodontal treatment adjunct.
• Metronidazole
Metronidazole is effective against anaerobic bacteria, and it is often combined with Amoxicillin for an enhanced antimicrobial effect as a periodontal treatment adjunct.

Other:
• Placebo
Placebo in identical drug-safe vials with capsules identical in appearance to the active drugs

Locations

Country	Name	City	State
United States	University of Alabame	Birmingham	Alabama

Sponsors (3)

Lead Sponsor	Collaborator
Rutgers, The State University of New Jersey	National Dental PBRN, National Institute of Dental and Craniofacial Research (NIDCR)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Treatment-related adverse events	The number and severity of adverse events related to SRP plus AMXM versus SRP plus placebo will be recorded to assess the safety of the intervention.	Through study completion, an average of 12 months
Primary	Probing Depth (PD) in millimeters	The primary outcome of treatment effectiveness will be assessed by full-mouth probing depth (PD) at 6 weeks to 12 months post-intervention adjusted for baseline PD. Full-mouth PD measurements (excluding 3rd molars) will be obtained utilizing a UNC 15mm periodontal probe.	Baseline, Re-evaluation (6 weeks), and Final study visit (12 months) after intervention.
Secondary	Clinical attachment level (CAL) in millimeters	This secondary objective will be assessed by clinical attachment level (CAL) changes from baseline to 6 weeks to 12 months post-intervention, adjusting for baseline CAL. CAL is a disease-related characteristic. Half-mouth CAL in millimeters (excluding 3rd molars) will be obtained utilizing a UNC 15mm periodontal probe to measure base of pocket to cementoenamel junction (CEJ).	Baseline, Re-evaluation (6 weeks), and Final study visit (12 months) after intervention.
Secondary	Changes in the probability of bleeding on probing (BoP)	This secondary objective will assess changes in the probability of observing BoP, a common surrogate for gingival inflammation, at 6 weeks to 12 months post intervention, adjusting for baseline BoP. BoP is assessed in conjunction with probing depths using a UNC 15mm periodontal probe and is recorded as a binary outcome per site, i.e., is the site bleeding? Yes/No.	Baseline, Re-evaluation (6 weeks), and Final study visit (12 months) after intervention.
Secondary	Reduction in diseased sites	Reduction in diseased sites is a calculated variable from PD. We will assess the probability a site is observed with residual PD= 5 mm at 6 weeks to 12 months post-intervention, adjusting for its baseline PD. PD= 5mm; The maximum probing depth per tooth will be recorded as =5 mm (yes/no).	Baseline, Re-evaluation (6 weeks), and Final study visit (12 months) after intervention.
Secondary	Disease remission	Disease remission is defined as the number of study patient participants who have =4 sites with PD=5mm. Patient participants will be considered 'in remission' if they display =4 sites with PD= 5mm; This is a dichotomization from the summation of PD= 5mm within person.	Baseline, Re-evaluation (6 weeks), and Final study visit (12 months) after intervention.
Secondary	Changes in oral health-related quality of life	To evaluate oral health-related quality of life, the Oral Health Impact Profile (OHIP-5) will be utilized. OHIP-5 sum score based upon self-reported responses will be assessed. The OHIP-5 has 5 questions ranging from 0 = never to 4 = very often with higher scores translating to a worse outcome.	Baseline, Re-evaluation (6 weeks), and Final study visit (12 months) after intervention.

External Links

•   Related Info